Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Regul Toxicol Pharmacol ; 123: 104960, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-34022260

RESUMO

Cassia occidentalis Linn (CO) is an annual/perennial plant having traditional uses in the treatments of ringworm, gastrointestinal ailments and piles, bone fracture, and wound healing. Previously, we confirmed the medicinal use of the stem extract (ethanolic) of CO (henceforth CSE) in fracture healing at 250 mg/kg dose in rats and described an osteogenic mode of action of four phytochemicals present in CSE. Here we studied CSE's preclinical safety and toxicity. CSE prepared as per regulations of Current Good Manufacturing Practice for human pharmaceuticals/phytopharmaceuticals and all studies were performed in rodents in a GLP-accredited facility. In acute dose toxicity as per New Drug and Clinical Trial Rules, 2019 (prior name schedule Y), in rats and mice and ten-day dose range-finding study in rats, CSE showed no mortality and no gross abnormality at 2500 mg/kg dose. Safety Pharmacology showed no adverse effect on central nervous system, cardiovascular system, and respiratory system at 2500 mg/kg dose. CSE was not mutagenic in the Ames test and did not cause clastogenicity assessed by in vivo bone marrow genotoxicity assay. By a sub chronic (90 days) repeated dose (as per OECD, 408 guideline) study in rats, the no-observed-adverse-effect-level was found to be 2500 mg/kg assessed by clinico-biochemistry and all organs histopathology. We conclude that CSE is safe up to 10X the dose required for its osteogenic effect.


Assuntos
Compostos Fitoquímicos/toxicidade , Extratos Vegetais/toxicidade , Senna , Animais , Etanol , Camundongos , Nível de Efeito Adverso não Observado , Ratos , Roedores , Testes de Toxicidade
2.
Sci Rep ; 10(1): 9102, 2020 06 04.
Artigo em Inglês | MEDLINE | ID: mdl-32499562

RESUMO

We determined the role of cellular fibronectin (CFN) containing the alternatively spliced extra domain A (FN-EDA) in causing insulin resistance (IR) through toll-like receptor 4 (TLR4). Circulating FN-EDA level was evaluated in mouse and rat IR models. Specific anti-FN-EDA antibody and TLR4 inhibitor were used to study its role in IR in mice. CFN protein was injected to evaluate TLR4 dependent effect of FN-EDA in IR. Furthermore, FN-EDA was estimated in blood plasma and correlated with demographic and clinical characteristics in healthy human participants (n = 38). High-fat diet feeding significantly increased circulating FN-EDA in both mouse (P = 0.03) and rat (P = 0.02) IR models. Antibody against FN-EDA protected mice from IR by increasing glucose disposal rate following glucose (P = 0.02) and insulin (P = 0.01) tolerance tests. CFN protein injection caused IR, however, TLR4 inhibitor protected the mice from CFN induced IR. Multivariate regression analysis predicted an independent positive correlation between circulating FN-EDA and fasting plasma glucose (P = 0.003) in healthy human participants. In conclusion, FN-EDA may cause IR through TLR4 by decreasing glucose disposal rate following glucose and insulin load. Targeting FN-EDA thus can be considered as a possible therapeutic strategy to delay prediabetes progression to diabetes.


Assuntos
Diabetes Mellitus/etiologia , Fibronectinas/efeitos adversos , Fibronectinas/fisiologia , Resistência à Insulina/genética , Receptor 4 Toll-Like/metabolismo , Animais , Glicemia/metabolismo , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/prevenção & controle , Modelos Animais de Doenças , Feminino , Fibronectinas/metabolismo , Voluntários Saudáveis , Humanos , Masculino , Camundongos Endogâmicos C57BL , Terapia de Alvo Molecular , Ratos , Sulfonamidas/farmacologia , Sulfonamidas/uso terapêutico , Receptor 4 Toll-Like/antagonistas & inibidores
3.
Mol Neurobiol ; 55(8): 6500-6517, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-29327199

RESUMO

Neurogenesis involves generation of functional newborn neurons from neural stem cells (NSCs). Insufficient formation or accelerated degeneration of newborn neurons may contribute to the severity of motor/nonmotor symptoms of Parkinson's disease (PD). However, the functional role of adult neurogenesis in PD is yet not explored and whether glycogen synthase kinase-3ß (GSK-3ß) affects multiple steps of adult neurogenesis in PD is still unknown. We investigated the possible underlying molecular mechanism of impaired adult neurogenesis associated with PD. Herein, we show that single intra-medial forebrain bundle (MFB) injection of 6-hydroxydopamine (6-OHDA) efficiently induced long-term activation of GSK-3ß and reduced NSC self-renewal, proliferation, neuronal migration, and neuronal differentiation accompanied with increased astrogenesis in subventricular zone (SVZ) and hippocampal dentate gyrus (DG). Indeed, 6-OHDA also delayed maturation of neuroblasts in the DG as witnessed by their reduced dendritic length and arborization. Using a pharmacological approach to inhibit GSK-3ß activation by specific inhibitor SB216763, we show that GSK-3ß inhibition enhances radial glial cells, NSC proliferation, self-renewal in the SVZ, and the subgranular zone (SGZ) in the rat PD model. Pharmacological inhibition of GSK-3ß activity enhances neuroblast population in SVZ and SGZ and promotes migration of neuroblasts towards the rostral migratory stream and lesioned striatum from dorsal SVZ and lateral SVZ, respectively, in PD model. GSK-3ß inhibition enhances dendritic arborization and survival of granular neurons and stimulates NSC differentiation towards the neuronal phenotype in DG of PD model. The aforementioned effects of GSK-3ß involve a crosstalk between Wnt/ß-catenin and Notch signaling pathways that are known to regulate NSC dynamics.


Assuntos
Glicogênio Sintase Quinase 3 beta/metabolismo , Neurogênese , Neuroglia/metabolismo , Doença de Parkinson/patologia , Receptores Notch/metabolismo , Via de Sinalização Wnt , Animais , Ciclo Celular , Diferenciação Celular , Movimento Celular , Dendritos/metabolismo , Modelos Animais de Doenças , Hipocampo/patologia , Ventrículos Laterais/patologia , Masculino , Células-Tronco Neurais/metabolismo , Oxidopamina , Fenótipo , Ratos Sprague-Dawley
4.
Pharmacol Biochem Behav ; 94(3): 397-403, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19808044

RESUMO

In the present study the effect of melatonin on intracerebroventricularly administered streptozotocin (STZ)-induced neurodegeneration was investigated in rats. STZ (3mg/kg), administered twice with an interval of 48 h between the two doses, showed impairment in spatial memory tested by water maze test after 14 days of 1st dose. Administration of melatonin (2.5, 5.0 and 10mg/kg, i.p.) was started 1h prior to 1st dose of STZ and continued up to 14 days. Glutathione and malondialdehyde were used as biochemical markers of oxidative stress in different brain regions. Histopathological changes were examined by using hematoxylin and eosin stain. STZ administration caused significant decrease in glutathione and increase in malondialdehyde as compared to control and artificial Cerebrospinal Fluid treated rats indicating oxidative stress. Brain sections of STZ-treated rats showed increased vacuoles in the periventricular cortical area, damaged periventricular cells and damaged cells in the hippocampal CA4 region as compared to control and artificial Cerebrospinal Fluid treated groups. Melatonin treatment significantly attenuated the effect of STZ-induced oxidative stress and histopathological changes. The results indicate that melatonin is effective in providing protection against memory deficit, oxidative stress and neuronal damage induced by STZ.


Assuntos
Melatonina/farmacologia , Memória/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Estreptozocina/administração & dosagem , Animais , Glicemia/análise , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Glutationa/metabolismo , Injeções Intraventriculares , Masculino , Aprendizagem em Labirinto , Estresse Oxidativo , Ratos , Ratos Sprague-Dawley , Estreptozocina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...